PODD News and Press, Insulet Corporation From 02/05/25

Shares of Insulet Corporation (NASDAQ: PODD) traded at a new 52-week high today and are currently trading at $285.14. So far today, approximately 114.87k shares have been exchanged, as compared to an average 30-day volume of 484.92k shares. Insulet Corporation develops, manufactures, and sell...

2025-02-02 09:43:20 ET Summary Beta Bionics' IPO was highly successful, trading 40% above the offer price due to strong growth prospects and relatively cheap sales multiples. The company’s iLet product offers a new, simplified treatment for Type 1 diabetes, with plans to ex...

2025-01-28 12:36:21 ET More on Beta Bionics, Inc. Beta Bionics Aims For IPO To Cover Heavy Losses Beta Bionics sets terms for upsized $113M IPO Diabetes device maker Beta Bionics files for $100M IPO Financial information for Beta Bionics, Inc. Read ...

2025-01-22 17:09:09 ET More on Beta Bionics, Inc. Beta Bionics Aims For IPO To Cover Heavy Losses Diabetes device maker Beta Bionics files for $100M IPO Financial information for Beta Bionics, Inc. Read the full article on Seeking Alpha For further de...

2025-01-13 17:26:27 ET More on Insulet Insulet: Superb Business Growth, Starting Valuations Outsized Risk Insulet Corporation: Significant Opportunities, Significant Threats - I'm On The Sidelines Insulet Corporation (PODD) Q3 2024 Earnings Call Transcript He...

The Omnipod 5 Automated Insulin Delivery System is now commercially available in Italy, Denmark, Finland, Norway, and Sweden with Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin p...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the fourth quarter and full year of 2024 on February 20, 2025, after the clos...

2025-01-07 16:44:46 ET More on Renaissance Capital Greenwich Funds - Renaissance IPO ETF IPO: Favorable Capital Markets In 2025 Not Yet A Tailwind (Rating Downgrade) IPO Roundup: Cortigent, Diginex and more Medtech test developer Anbio files for $9M US IPO Se...

2025-01-07 11:17:52 ET More on SPDR S&P 500 ETF Trust: S&P 500 In 2025: Trump Vs. AI Vs. Fed My View Of The S&P 500 Index: January 2025 Edition (Technical Analysis) Major Signals Point To Market Top: Investment Risk Mitigation Is Prudent Now ETF f...

2025-01-06 14:57:38 ET More on iShares Russell 1000 ETF: The Dollar And Domestics 10 BofA U.S. options overwriting ideas Morgan Stanley lists hedge funds’ largest Q3 ownership increases in Russell 1000 stocks Seeking Alpha’s Quant Rating on iSha...